## **Research Article**



# RAGE-mediated functional DNA methylated modification contributes to cigarette smoke-induced airway inflammation in mice

## Ping Li<sup>1,\*</sup>, Tao Wang<sup>1,\*</sup>, Mei Chen<sup>2,\*</sup>, Jun Chen<sup>1</sup>, <sup>(b)</sup> Yongchun Shen<sup>1</sup> and <sup>(b)</sup> Lei Chen<sup>1</sup>

<sup>1</sup>Laboratory of Pulmonary Diseases and Department of Respiratory and Critical Care Medicine, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, P.R. China; <sup>2</sup>Department of Respiratory and Critical Care Medicine, Chengdu Fifth People's Hospital, Chengdu, Sichuan 611130, P.R. China

Correspondence: Lei Chen (Ichens@126.com) or Yongchun Shen (shen\_yongchun@126.com)



Our previous study indicated knockout of receptor for advanced glycation end-products (RAGE) significantly attenuated cigarette smoke (CS)-induced airway inflammation in mice. In the present study, we aim to further detect the mediatory effects of RAGE in DNA methylated modification in CS-induced airway inflammation. Lung tissues from the CS-exposed mouse model of airway inflammation were collected for profiling of DNA methylation by liguid hybridization capture-based bisulfite sequencing, which were used for conjoint analysis with our previous data of gene expression by cDNA microarray to identify functional methylated genes, as well as hub genes selected by protein-protein interaction (PPI) network analysis, and functional enrichment analyses were then performed. After RAGE knockout, 90 genes were identified by intersection of the differentially methylated genes and differentially expressed genes. According to the reversed effects of methylation in promoters on gene transcription, 14 genes with functional methylated modification were further identified, among which chemokine (C-X-C motif) ligand 1 (CXCL1), Toll-like receptor 6 (TLR6) and oncostatin M (OSM) with hypomethylation in promoters, were selected as the hub genes by PPI network analysis. Moreover, functional enrichment analyses showed the 14 functional methylated genes, including the 3 hub genes, were mainly enriched in immune-inflammatory responses, especially mitogen-activated protein kinase, tumor necrosis factor, TLRs, interleukin (IL)-6 and IL-17 pathways. The present study suggests that RAGE mediates functional DNA methylated modification in a cluster of 14 targeted genes, particularly hypomethylation in promoters of CXCL1, TLR6 and OSM, which might significantly contribute to CS-induced airway inflammation via a network of signaling pathways.

## \*These authors contributed equally to this work.

Received: 06 February 2021 Revised: 14 May 2021 Accepted: 17 May 2021


Accepted Manuscript online: 21 May 2021 Version of Record published: 29 June 2021

## Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation that are associated with persistent airway inflammation induced by cigarette smoke (CS), a major causative factor for COPD [1].

Receptor for advanced glycation end-products (RAGE), a membrane protein from the immunoglobulin superfamily, has been implicated in the pathogenesis of COPD [2]. Overexpression of RAGE contributed to airway inflammation in CS-associated COPD [3]. Our previous study further indicated knockout (KO) of RAGE gene significantly attenuated CS-induced airway inflammation in a mouse model [4]. However, the mechanisms regarding the effects of RAGE on airway inflammation in COPD remain not clear. Recently, some evidences implied DNA methylation, an epigenetic regulation, played important





### Figure 1. Venn diagram of the intersection model

The colorful oval shapes represent CS-associated DEGs (yellow), CS-associated DMGs (blue), RAGE-associated DEGs (green) and RAGE-associated DMGs (purple).

roles in RAGE-mediated inflammatory responses in various diseases [5–7], although the role in DNA methylated modification mediated by RAGE in airway inflammation in COPD was not reported.

In consequence, we did the present study, using the established mouse model of CS-induced airway inflammation, to explore the underlying mechanisms of RAGE-mediated DNA methylated modification in airway inflammation in COPD.

## Materials and methods Animal model

The animal model of CS-induced airway inflammation has been established in our former study [4]. C57BL/6 mice (7–9 weeks old, 20–22 g weight) were used to generate RAGE KO mice through CRISPR/Cas9 gene targeting technology by Bioray Biotechnology (Shanghai, China). The four experimental groups (n=3 mice per group) were included in the present study, as follows: (i) wildtype (WT) group, (ii) CS+WT group, (iii) CS+KO group, (iv) WT+KO group. All mice were specific pathogen-free and kept on a 12-h light/12-h dark cycle, at a room temperature of  $22 \pm 2^{\circ}$ C, with free access to food and water. WT and RAGE KO mice were exposed to mainstream CS or room air for 2 h twice daily, 6 days per week for consecutive 4 weeks. After 4-week CS exposure, the mice were anesthetized intraperitoneally with pentobarbital sodium and killed by femoral artery transection. The animal study was approved by the Panel on Laboratory Animal Care of West China Hospital of Sichuan University and took place at the Experimental Animal Center of West China Hospital of Sichuan University.


## **DNA** extraction

The total DNA of lung tissues was extracted and purified by DNeasy Blood Tissue Kit (Qiagen), according to the manufacturer's instructions. Purified DNA was then quantified by NanoDrop2000 Spectrophotometer (Thermo) and agarose gel electrophoresis. Only DNA samples with  $A_{260/280}$  ratio between 1.8 and 2.0 were used for further experiments.

## Liquid hybridization capture-based bisulfite sequencing

Genomic DNA (1  $\mu$ g per sample) was randomly fragmented into approximately 200–300 bp by sonication. After purification, the DNA fragments were repaired in the blunt and phosphorylated ends, which were subsequently 3'





### Figure 2. PPI network analysis of the candidate genes

Edges indicate correlations between two genes. The bigger circles indicate more related genes and red circles indicate the hub genes.

adenylated and then ligated to the methylated adapter using the SureSelect<sup>XT</sup> Mouse methyl-seq Library Prep Kit (Agilent). After that, the DNA hybridization was performed using the SureSelect<sup>™</sup> Methyl-SeQ Hybridization Kit (Agilent), which covered 100 Mb of mouse genomic regions, including CpG islands, Gencode promoters, tissue-specific differential methylated regions (DMRs) and DNase I hypersensitive sites. The hybridized DNA was subsequently bisulfite-treated using the EZ DNA Methylation-Gold<sup>™</sup> Kit (Zymo Research) to convert unmethylated cytosine into uracil according to the manufacturer's instructions. Finally, the treated DNA was amplified by polymerase chain reaction (PCR) and sequenced on Illumina Novaseq PE150.

## **DNA** methylation data analyses

The Fastp software (version 1.2.1) was used to process methylated raw data and remove the low quality reads, including (i) contaminated sequences; (ii) the Q-value of 3' end is less than 20; (iii) reads with less than 15 bp; (iv) reads with 40% base Q-value less than 15; (v) reads containing N bases greater than 5 ( $Q = -10*\log 10(P)$ , *P* is the probability of error) [8]. The clean reads were aligned to the reference genome using Bismark software (version 0.19.0) with bowtie2 (version 2.3.4.2) to attain the methylated type, status and proportion [9]. DMRs were subsequently analyzed using the R package methylKit (version 1.6.1) [10] and eDMR [11], with an adjusted *P*-value <0.05 and absolute differential



methylation levels (absolute meth. diff > 5%). Finally, related differential methylated genes (DMGs) were located and annotated in the DMRs by the ChIPseeker software.

## **cDNA** microarray

The data of gene expression by cDNA microarray have been obtained in our former study [4]. In the present study, differentially expressed genes (DEGs) were identified by fold-change, and only genes that at least 1.2-fold up-regulated or down-regulated were analyzed.

## **Candidate genes selection**

To identify the candidate genes with methylated modification mediated by RAGE, a novel intersection model was performed (Figure 1). Briefly, CS-associated (CS+WT vs WT) and RAGE-associated (CS+KO vs CS+WT plus WT+KO vs WT) DMGs intersected to get the overlapped DMGs, and so did CS-associated and RAGE-associated DEGs (overlapped DEGs). Then, the overlapped DMGs and DEGs intersected again to select the candidate genes.

## Functional methylated genes and hub genes selection

The candidate genes with functional methylated modification, also called functional methylated genes, were identified according to the reversed effects of methylation in promoters on gene transcription. To further identify the hub genes that were most correlated with other genes, protein–protein interaction (PPI) network analysis among the functional methylated genes was performed using the online database STRING [12] and displayed using Cytoscape [13].

## **Functional enrichment analyses**

Functional enrichment analyses on the functional methylated genes, as well as the hub genes, using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were performed with the clusterProfiler package using P-value <0.05 was set as the threshold.

# Results Data production

Based on the liquid hybridization capture-based bisulfite sequencing (LHC-BS) method, 15 Gbp raw sequence data were generated on average for each sample. More than 79% were mapped to at less one genomic position, covering  $\sim$ 77% of the target regions, with an average of 57× sequencing depth per CpG and 12.5% duplication data, and the duplicated sequence reads were filtered for the subsequent analyses.

## **RAGE-mediated functional DNA methylated modification in targeted** genes in CS-induced airway inflammation

After RAGE KO, as reported in our previous study, CS-induced airway inflammation was significantly improved [4]. Meanwhile, 90 overlapping candidate genes were identified via the intersection of DMGs with DEGs (Supplementary Table S1). It is well-known that DNA methylation occurs almost in CpG islands that are primarily located in the regions of promoter and are negatively correlated with gene expression [14]. As a result, 14 genes from the 90 candidate genes, with functional methylated modification in promoters were identified (Table 1), among which, three genes, including chemokine (C–X–C motif) ligand 1 (CXCL1), Toll-like receptor 6 (TLR6) and oncostatin M (OSM) with hypomethylation in promoters were finally selected as the hub genes by PPI network analysis (Figure 2). Furthermore, GO and KEGG analyses indicated the 14 functional methylated genes, including the 3 hub genes, were significantly enriched in immune-inflammatory responses, especially mitogen-activated protein kinase (MAPK), tumor necrosis factor (TNF), TLRs, interleukin (IL)-6 and IL-17 signaling pathways (Supplementary Tables S2 and S3).

## Discussion

DNA methylation is closely associated with COPD susceptibility, exacerbation and lung function decline [15,16]. In this process, RAGE may play a regulatory role in DNA methylated modification in COPD, whereas the mechanisms remain unexplained. Consequently, in the present study, the 90 DMGs, regarding RAGE-mediated airway inflammation induced by CS exposure, were initially selected using a novel intersection model, and the functional DNA methylated modification in 14 targeted genes were subsequently identified, especially hypomethylation in CXCL1, TLR6 and OSM promoters, which might significantly contribute to RAGE-mediated airway inflammation in COPD via a network of signaling pathways, such as MAPK, TNF, TLRs, ILs, etc.



Gene	Description	Genomic localization	Methylation change <sup>*</sup>	Fold change
Alox5ap	Aachidonate 5-lipoxygenase activating protein	Promoter Distal intergenic 3' UTR	Hyper (15.6131412) Hypo (–12.032621795) Hypo (–13.27280036)	-1.2
Arhgap22	Rho GTPase activating protein 22	Promoter Promoter	Hyper (10.29366302) Hypo (–6.476953839)	-1.3
Cxcl1	Chemokine (C–X–C motif) ligand 1	Promoter	Hyper (10.2010746)	-1.2
Dmc1	DNA meiotic recombinase 1	Promoter	Нуро (9.450360901)	1.2
Inf2	Iverted formin, FH2 and WH2 domain containing	Promoter Distal intergenic	Hyper (13.93768033) Hyper (13.60386215)	-1.2
Mir1981	MicroRNA 1981	Promoter	Нуро (-6.417671883)	1.2
Mmp25	Matrix metallopeptidase 25	Promoter Promoter	Hyper (15.40303433) Hypo (—13.06629416)	-1.4
Osm	Oncostatin M	Promoter	Hyper (15.05770235)	-1.4
Psmb9	Proteasome 20S subunit $\beta$ 9	Promoter	Hyper (10.74327874)	-1.3
Rnaseh2b	Ribonuclease H2, subunit B	Promoter	Hyper (11.78927527)	-1.3
Slc16a6	Solute carrier family 16 member 6	Promoter Intron	Hyper (8.126762879) Hyper (8.360891276)	-1.2
Srgn	Srglycin	Promoter	Hyper (9.932392771)	-1.3
Tlr6	Toll-like receptor 6	Promoter	Hyper (17.51844104)	-1.4
Tmod2	Tropomodulin 2	Promoter	Нуро (-7.597567585)	1.3

#### Table 1 The 14 functional methylated genes

\*Methylation changes (%) in gene expression by CS+KO vs CS+WT. Abbreviations: Hyper, hypermethylation; Hypo, hypomethylated; Inc, increased variance.

According to the GO and KEGG analyses, the majority of the candidate genes, especially the 14 functional methylated genes widely participated in CS-associated inflammatory-immune responses. In particular, the three hub genes were documented to play important roles in the inflammatory process in COPD. CXCL1 is a member of chemokine subfamily of CXC [17] and the increased level of CXCL1 was detected in the lungs of COPD [18]. CXCL1 served as a chemoattractant for neutrophils migrating from circulation to respiratory tracts, which contributed to neutrophilic inflammation of COPD [19]. TLR6 belongs to the Toll-like receptor family [20], which initiates innate immune responses in airway epithelial cells and triggers inflammatory responses [21]. Furthermore, TLRs activation could increase CXCL1 production in human pulmonary macrophages [22]. OSM, a member of IL-6 subfamily [23], participates in a variety of inflammatory diseases with a high level [24–26]. In COPD, the inflammatory mechanisms for OSM may be stimulating IL-6 production and IL-6 related inflammation, which is positively correlated with pulmonary function decline [23,27]. Noticeably, as suggested in our study, CXCL1, TLR6 and OSM have been documented to be targeted genes of DNA methylated modification in other diseases, such as schizophrenia [28], type 1 diabetes [29] and Richter syndrome [30].

However, some limitations in the present study should be considered. First, the sample size of mice in each group was relatively small, although the minimum requirement for biological repeat was reached. Second, the novel intersection model might be theoretically imperfect. Third, validation was thus needed in future studies.

In summary, the present study performed intersections of DMGs with DEGs in a CS-exposed mouse model and indicated RAGE could mediate functional methylated modification in multiple targeted genes, especially CXCL1, TLR6 and OSM, which might significantly contribute to airway inflammation in COPD.

### **Data Availability**

The data presented in this manuscript are available from the corresponding author (Lei Chen) on reasonable request.

### **Competing Interests**

The authors declare that there are no competing interests associated with the manuscript.

### Funding

This work was supported by the National Natural Science Foundation of China [grant number 81970040].



### **CRediT Author Contribution**

**Ping Li:** Software, Investigation, Visualization, Methodology, Writing—original draft. **Tao Wang:** Software, Investigation, Visualization, Methodology. **Mei Chen:** Software, Investigation, Visualization, Methodology. **Jun Chen:** Software, Investigation. **Yongchun Shen:** Data curation, Supervision, Validation, Writing—review and editing. **Lei Chen:** Conceptualization, Formal Analysis, Writing—review and editing, Funding acquisition.

### Abbreviations

COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; CXCL1, chemokine (C–X–C motif) ligand 1; DEG, differentially expressed gene; DMG, differential methylated gene; DMR, differential methylated region; GO, Gene Ontology; IL, interleukin; KEGG, Kyoto Encyclopedia of Genes and Genomes; KO, knockout; MAPK, mitogen-activated protein kinase; OSM, oncostatin M; PPI, protein–protein interaction; RAGE, receptor for advanced glycation end-product; TLR, Toll-like receptor; TNF, tumor necrosis factor; WT, wildtype.

### References

- 1 Vogelmeier, C.F., Criner, G.J., Martinez, F.J., Anzueto, A., Barnes, P.J., Bourbeau, J. et al. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am. J. Respir. Crit. Care Med. 195, 557–582, https://doi.org/10.1164/rccm.201701-0218PP
- 2 Yonchuk, J.G., Silverman, E.K., Bowler, R.P., Agustí, A., Lomas, D.A., Miller, B.E. et al. (2015) Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. *Am. J. Respir. Crit. Care Med.* **192**, 785–792, https://doi.org/10.1164/rccm.201501-0137PP
- 3 Chen, L., Wang, T., Guo, L.L., Shen, Y.C., Yang, T., Wan, C. et al. (2014) Overexpression of RAGE contributes to cigarette smoke-induced nitric oxide generation in COPD. *Lung* **192**, 267–275, https://doi.org/10.1007/s00408-014-9561-1
- 4 Chen, M., Wang, T., Shen, Y., Xu, D., Li, X., An, J. et al. (2017) Knockout of RAGE ameliorates mainstream cigarette smoke-induced airway inflammation in mice. *Int. Immunopharmacol.* **50**, 230–235, https://doi.org/10.1016/j.intimp.2017.06.018
- 5 Kan, S., Wu, J., Sun, C., Hao, J. and Wu, Z. (2018) Correlation between RAGE gene promoter methylation and diabetic retinal inflammation. *Exp. Ther. Med.* **15**, 242–246
- 6 Maslinska, D., Laure-Kamionowska, M. and Maslinski, S. (2014) Methyl-CpG binding protein 2, receptors of innate immunity and receptor for advanced glycation end-products in human viral meningoencephalitis. *Folia Neuropathol.* **52**, 428–435, https://doi.org/10.5114/fn.2014.47844
- 7 Zhang, M., Li, Y., Rao, P., Huang, K., Luo, D., Cai, X. et al. (2018) Blockade of receptors of advanced glycation end products ameliorates diabetic osteogenesis of adipose-derived stem cells through DNA methylation and Wnt signalling pathway. *Cell Prolif.* 51, e12471, https://doi.org/10.1111/cpr.12471
- 8 Chen, S.F., Zhou, Y.Q., Chen, Y.R. and Gu, J. (2018) fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics* 34, 884–890, https://doi.org/10.1093/bioinformatics/bty560
- 9 Krueger, F. and Andrews, S.R. (2011) Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics* 27, 1571–1572, https://doi.org/10.1093/bioinformatics/btr167
- 10 Akalin, A., Kormaksson, M., Li, S., Garrett-Bakelman, F.E., Figueroa, M.E., Melnick, A. et al. (2012) methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. *Genome Biol.* **13**, R87, https://doi.org/10.1186/gb-2012-13-10-r87
- 11 Li, S., Garrett-Bakelman, F.E., Akalin, A., Zumbo, P., Levine, R., To, B.L. et al. (2013) An optimized algorithm for detecting and annotating regional differential methylation. *BMC Bioinformatics* **14**, S10, https://doi.org/10.1186/1471-2105-14-S5-S10
- 12 Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M. et al. (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. *Nucleic Acids Res.* **45**, D362–D368, https://doi.org/10.1093/nar/gkw937
- 13 Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D. et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504, https://doi.org/10.1101/gr.1239303
- 14 Bender, C.M., Gonzalgo, M.L., Gonzales, F.A., Nguyen, C.T., Robertson, K.D. and Jones, P.A. (1999) Roles of cell division and gene transcription in the methylation of CpG islands. *Mol. Cell. Biol.* **19**, 6690–6698, https://doi.org/10.1128/MCB.19.10.6690
- 15 Vucic, E.A., Chari, R., Thu, K.L., Wilson, I.M., Cotton, A.M., Kennett, J.Y. et al. (2014) DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways. *Am. J. Respir. Cell Mol. Biol.* **50**, 912–922, https://doi.org/10.1165/rcmb.2013-03040C
- 16 Busch, R., Qiu, W.L., Lasky-Su, J., Morrow, J., Criner, G. and DeMeo, D. (2016) Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations. *Respir. Res.* **17**, 15, https://doi.org/10.1186/s12931-016-0459-8
- 17 Charo, I.F. and Ransohoff, R.M. (2006) Mechanisms of disease The many roles of chemokines and chemokine receptors in inflammation. *N. Engl. J. Med.* **354**, 610–621, https://doi.org/10.1056/NEJMra052723
- 18 Traves, S.L., Culpitt, S.V., Russell, R.E.K., Barnes, P.J. and Donnelly, L.E. (2002) Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. *Thorax* 57, 590–595, https://doi.org/10.1136/thorax.57.7.590
- 19 Hikichi, M., Mizumura, K., Maruoka, S. and Gon, Y. (2019) Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. *J. Thorac. Dis.* **11**, S2129–S2140, https://doi.org/10.21037/jtd.2019.10.43
- 20 Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N.G., Gilbert, D.J., Jenkins, N.A. et al. (1999) TLR6: a novel member of an expanding Toll-like receptor family. *Gene* 231, 59–65, https://doi.org/10.1016/S0378-1119(99)00098-0



- 21 Koff, J.L., Shao, M.X.G., Ueki, I.F. and Nadel, J.A. (2008) Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **294**, L1068–L1075, https://doi.org/10.1152/ajplung.00025.2008
- 22 Grassin-Delyle, S., Abrial, C., Salvator, H., Brollo, M., Naline, E. and Devillier, P. (2020) The role of Toll-like receptors in the production of cytokines by human lung macrophages. J. Innate Immun. 12, 63–73, https://doi.org/10.1159/000494463
- 23 Tanaka, M. and Miyajima, A. (2003) Oncostatin M, a multifunctional cytokine. *Rev. Physiol. Biochem. Pharmacol.* **149**, 39–52, https://doi.org/10.1007/s10254-003-0013-1
- 24 Hasegawa, M., Sato, S., Fujimoto, M., Ihn, H., Kikuchi, K. and Takehara, K. (1998) Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25, 308–313
- 25 Pradeep, A.R., S, T.M., Garima, G. and Raju, A. (2010) Serum levels of oncostatin M (a gp 130 cytokine): an inflammatory biomarker in periodontal disease. *Biomarkers* 15, 277–282, https://doi.org/10.3109/13547500903573209
- 26 Liang, H., Block, T.M., Wang, M., Nefsky, B., Long, R., Hafner, J. et al. (2012) Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. *Cancer Biomark*. **11**, 161–171, https://doi.org/10.3233/CBM-2012-00276
- 27 Rincon, M. and Irvin, C.G. (2012) Role of IL-6 in asthma and other inflammatory pulmonary diseases. *Int. J. Biol. Sci.* 8, 1281–1290, https://doi.org/10.7150/ijbs.4874
- 28 Zhou, C., Chen, J., Tang, X., Feng, X., Yu, M., Sha, W. et al. (2018) DNA methylation and gene expression of the chemokine (C-X-C motif) ligand 1 in patients with deficit and non-deficit schizophrenia. *Psychiatry Res.* 268, 82–86, https://doi.org/10.1016/j.psychres.2018.06.067
- 29 Xie, Z., Huang, G., Wang, Z., Luo, S., Zheng, P. and Zhou, Z. (2018) Epigenetic regulation of Toll-like receptors and its roles in type 1 diabetes. J. Mol. Med. 96, 741–751, https://doi.org/10.1007/s00109-018-1660-7
- 30 Rinaldi, A., Mensah, A.A., Kwee, I., Forconi, F., Orlandi, E.M., Lucioni, M. et al. (2013) Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. *Br. J. Haematol.* **163**, 194–204

## Table S1. The 90 candidate genes selected according to the methylation and gene expression

Gene	Description	Genomic localization	Methylation change*	Fold Change
1600014C10Rik	RIKEN cDNA 1600014C10 gene	Promoter/Intron	Hypo/Hyper	-1.3
2610035D17Rik	RIKEN cDNA 2610035D17 gene	Intron	Inc	1.3
2610528J11Rik	RIKEN cDNA 2610528J11 gene	Promoter/Distal Intergenic	Нуро/Нуро	-1.3
Agpat4	1-acylglycerol-3-phosphate O-acyltransferase 4	Intron	Inc	-1.3
Alox5ap	arachidonate 5-lipoxygenase activating protein	Promoter/Distal Intergenic/3' UTR	Hyper/Hypo/Hypo	-1.2
Arhgap22	Rho GTPase activating protein 22	Promoter	Inc	-1.3
Atoh8	atonal bHLH transcription factor 8	Intron /Distal Intergenic	Нуро/Нуро	-1.7
Best2	bestrophin 2	3' UTR	Нуро	1.2
Blm	Bloom syndrome, RecQ like helicase	Exon/3' UTR	Inc/Hypo	-1.2
Btg3	B cell translocation gene 3	Intron/Distal Intergenic	Hyper/Hyper	-1.6
Cd80	CD80 antigen	Intron/Exon	Нуро/Нуро	-1.3
Cd84	CD84 antigen	Promoter /Intron/Distal Intergenic/3' UTR	Hyper/Hyper/Hyper/Hypo	1.3
Cdc6	cell division cycle 6	3' UTR	Нуро	-1.3
Ceacam2	carcinoembryonic antigen-related cell adhesion molecule 2	Intron	Hyper	1.3
Cebpb	CCAAT/enhancer binding protein (C/EBP), beta	Promoter/Intron	Hypo/Hyper	-1.3
Ckap4	cytoskeleton-associated protein 4	Distal Intergenic	Hyper	-1.4
Cxcl1	chemokine (C-X-C motif) ligand 1	Promoter	Hyper	-1.2
Dmc1	DNA meiotic recombinase 1	Promoter	Нуро	1.2
Dusp6	dual specificity phosphatase 6	Exon/Distal Intergenic	Hyper/Hyper	-1.7
Ear1	eosinophil-associated, ribonuclease A family, member 1	Distal Intergenic	Hyper	1.7
Emilin2	elastin microfibril interfacer 2	Exon/Intron/Downstream	Hyper/Inc/Hyper	-1.5
F2r	coagulation factor II (thrombin) receptor	Exon/Distal Intergenic/Downstream	Hyper/Hyper/Hyper	-1.3

Fn1	fibronectin 1	Exon/Distal Intergenic	Hyper/Hypo	-1.7
Galnt15	polypeptide N-acetylgalactosaminyltransferase 15	Promoter	Нуро	-1.3
Galnt2	polypeptide N-acetylgalactosaminyltransferase 2	Intron	Hyer	-1.3
Galnt9	polypeptide N-acetylgalactosaminyltransferase 9	Intron	Inc	-1.3
Gelc	glutamate-cysteine ligase, catalytic subunit	Distal Intergenic	Нуро	1.6
Gdf10	growth differentiation factor 10	Intron	Hyper	-1.3
Gm3696	predicted gene 3696	Intron	Hyper	1.6
Gm5148	predicted gene 5148	Distal Intergenic	Inc	-1.2
Gm6548	eukaryotic translation elongation factor 1 alpha 1 pseudogene	Promoter	Hyper	1.3
Gm8300	predicted gene 8300	Distal Intergenic	Hyper	1.6
Gp6	glycoprotein 6 (platelet)	Distal Intergenic	Hyper	-1.2
Gsg11	GSG1-like	Promoter	Hyper	1.2
Ifitm2	interferon induced transmembrane protein 2	Promoter	Нуро	-1.5
Ifitm2 Inf2	interferon induced transmembrane protein 2 inverted formin, FH2 and WH2 domain containing	Promoter Promoter/Distal Intergenic	Hypo Hyper/Hyper	-1.5
Inf2	inverted formin, FH2 and WH2 domain containing	Promoter/Distal Intergenic	Hyper/Hyper	-1.2
Inf2 Irak3	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3	Promoter/Distal Intergenic Intron	Hyper/Hyper Inc	-1.2
Inf2 Irak3 Kcnj8	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8	Promoter/Distal Intergenic Intron Distal Intergenic	Hyper/Hyper Inc Inc	-1.2 -1.3 -1.3
Inf2 Irak3 Kcnj8 Kdr	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8 kinase insert domain protein receptor	Promoter/Distal Intergenic Intron Distal Intergenic Exon/Distal Intergenic	Hyper/Hyper Inc Inc Hyper/Hypo	-1.2 -1.3 -1.3 1.4
Inf2 Irak3 Kcnj8 Kdr Krt18	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8 kinase insert domain protein receptor keratin 18	Promoter/Distal Intergenic Intron Distal Intergenic Exon/Distal Intergenic Promoter/Distal Intergenic	Hyper/Hyper Inc Inc Hyper/Hypo Hypo/Hypo	-1.2 -1.3 -1.3 1.4 -1.5
Inf2 Irak3 Kcnj8 Kdr Krt18 Ldb2	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8 kinase insert domain protein receptor keratin 18 LIM domain binding 2	Promoter/Distal Intergenic Intron Distal Intergenic Exon/Distal Intergenic Promoter/Distal Intergenic Intron	Hyper/Hyper Inc Inc Hyper/Hypo Hypo/Hypo	-1.2 -1.3 -1.3 1.4 -1.5 -1.2
Inf2 Irak3 Kcnj8 Kdr Krt18 Ldb2 Lgj2	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8 kinase insert domain protein receptor keratin 18 LIM domain binding 2 leucine-rich repeat LGI family, member 2	Promoter/Distal Intergenic Intron Distal Intergenic Exon/Distal Intergenic Promoter/Distal Intergenic Intron Distal Intergenic	Hyper/Hyper Inc Inc Hyper/Hypo Hypo/Hypo Hyper	-1.2 -1.3 -1.3 1.4 -1.5 -1.2 -1.2
Inf2 Irak3 Kcnj8 Kdr Krt18 Ldb2 Lgi2 Lmnb1	inverted formin, FH2 and WH2 domain containing interleukin-1 receptor-associated kinase 3 potassium inwardly-rectifying channel, subfamily J, member 8 kinase insert domain protein receptor keratin 18 LIM domain binding 2 leucine-rich repeat LGI family, member 2 lamin B1	Promoter/Distal Intergenic         Intron         Distal Intergenic         Exon/Distal Intergenic         Promoter/Distal Intergenic         Intron         Distal Intergenic         Distal Intergenic         Distal Intergenic         Distal Intergenic         Distal Intergenic	Hyper/Hyper Inc Inc Hyper/Hypo Hypo/Hypo Hyper Hyper	-1.2 -1.3 -1.3 1.4 -1.5 -1.2 -1.2 -1.2

Mir1981	microRNA 1981	Promoter	Нуро	1.2
Mmp25	matrix metallopeptidase 25	Promoter	Inc	-1.4
Mthfd11	methylenetetrahydrofolate dehydrogenase (NADP+ Dependent) 1 Like	Exon	Нуро	-1.4
Myo18b	myosin XVIIIb	Intron/Exon	Нуро/Нуро	1.2
Nav2	neuron navigator 2	Intron	Inc	1.2
Ncf1	neutrophil cytosolic factor 1	Intron/3' UTR	Нуро/Нуро	-1.3
Ntrk2	neurotrophic tyrosine kinase, receptor, type 2	Intron	Нуро	-1.6
Nupl2	nucleoporin like 2	Intron	Hyper	1.3
Osm	oncostatin M	Promoter	Hyper	-1.4
Padi4	peptidyl arginine deiminase, type IV	Exon/Downstream	Hyper/Hypo	-1.6
Pgam2	phosphoglycerate mutase 2	Promoter	Hyper	1.3
Pgm1	phosphoglucomutase 1	Exon/Distal Intergenic	Hyper/Hyper	-1.4
Pln	phospholamban	Distal Intergenic	Hyper	1.5
Pln Ppargc1a	phospholamban peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Distal Intergenic Distal Intergenic	Hyper Hypo	1.5 -1.3
Pparge 1 a	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Distal Intergenic	Нуро	-1.3
Ppargc1a Prkar2b	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta	Distal Intergenic Intron/Exon/Distal Intergenic	Hypo Hyper/Hyper/Hyper	-1.3 1.4
Ppargc1a Prkar2b Psmb9	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9	Distal Intergenic Intron/Exon/Distal Intergenic Promoter	Hypo Hyper/Hyper/Hyper Hyper	-1.3 1.4 -1.3
Ppargc1a Prkar2b Psmb9 Pttg1	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9 pituitary tumor-transforming gene 1	Distal Intergenic Intron/Exon/Distal Intergenic Promoter Promoter	Hypo Hyper/Hyper/Hyper Hyper Hyper	-1.3 1.4 -1.3 1.3
Pparge1a Prkar2b Psmb9 Pttg1 Rcsd1	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9 pituitary tumor-transforming gene 1 RCSD domain containing 1	Distal Intergenic Intron/Exon/Distal Intergenic Promoter Promoter Distal Intergenic	Hypo Hyper/Hyper Hyper Hypo	-1.3 1.4 -1.3 1.3 -1.2
Pparge1a Prkar2b Psmb9 Pttg1 Resd1 Rerg	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9 pituitary tumor-transforming gene 1 RCSD domain containing 1 RAS-like, estrogen-regulated, growth-inhibitor	Distal Intergenic Intron/Exon/Distal Intergenic Promoter Distal Intergenic Promoter/Intron	Hypo Hyper/Hyper/Hyper Hyper Hypo	-1.3 1.4 -1.3 1.3 -1.2 -1.2
Ppargc1a Prkar2b Psmb9 Pttg1 Rcsd1 Rerg Rfc5	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9 pituitary tumor-transforming gene 1 RCSD domain containing 1 RAS-like, estrogen-regulated, growth-inhibitor replication factor C (activator 1) 5	Distal Intergenic Intron/Exon/Distal Intergenic Promoter Distal Intergenic Promoter/Intron Distal Intergenic	Hypo Hyper/Hyper/Hyper Hyper Hypo/Hyper Hypo/Hyper	-1.3 1.4 -1.3 1.3 -1.2 -1.2 -1.2
Ppargc1a Prkar2b Psmb9 Pttg1 Rcsd1 Rerg Rfc5 Rnaseh2b	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha protein kinase, cAMP dependent regulatory, type II beta proteasome 20S subunit beta 9 pituitary tumor-transforming gene 1 RCSD domain containing 1 RAS-like, estrogen-regulated, growth-inhibitor replication factor C (activator 1) 5 ribonuclease H2, subunit B	Distal Intergenic Intron/Exon/Distal Intergenic Promoter Promoter Distal Intergenic Distal Intergenic Distal Intergenic	Hypo Hyper/Hyper/Hyper Hyper Hypo Hypo/Hyper Hyper	-1.3 1.4 -1.3 1.3 -1.2 -1.2 -1.3 -1.3

Slc1a5	solute carrier family 1 member 5	Exon/Distal Intergenic	Inc/Hyper	1.3
Slc7a5	solute carrier family 7 member 5	Distal Intergenic	Hyper	-1.5
Slc7a8	solute carrier family 7 member 8	Intron/Distal Intergenic	Hyper/Hyper	-1.3
Socs3	suppressor of cytokine signaling 3	Distal Intergenic	Hyper	-1.6
Spata18	spermatogenesis associated 18	Distal Intergenic	Inc	1.5
Srgn	serglycin	Promoter	Hyper	-1.3
Srp9	signal recognition particle 9	Intron/Distal Intergenic	Hyper/Inc	-1.2
St3gal1	ST3 beta-galactoside alpha-2,3-sialyltransferase 1	Intron /Distal Intergenic	Hyper/Hyper	-1.2
Tbc1d30	TBC1 domain family, member 30	Promoter/Exon/3' UTR	Hyper/Hypo/Hyper	1.2
Thy 1	thymus cell antigen 1, theta	Promoter	Нуро	-1.3
Timm22	translocase of inner mitochondrial membrane 22	Intron/Exon	Нуро/Нуро	-1.4
Tlr6	toll-like receptor 6	Promoter	Hyper	-1.4
Tmem45b	transmembrane protein 45b	Distal Intergenic	Inc	1.5
Tmod2	tropomodulin 2	Promoter	Нуро	1.3
Tnfrsf1a	tumor necrosis factor receptor superfamily, member 1a	3' UTR	Нуро	-1.2
Vasp	vasodilator-stimulated phosphoprotein	Downstream	Hyper	-1.3
Vmn2r33	vomeronasal 2, receptor 33	Distal Intergenic	Hyper	1.6
Wfs1	wolframin ER transmembrane glycoprotein	Intron	Hyper	-1.3
Zbp1	Z-DNA binding protein 1	Intron	Нуро	-1.3
Zbtb20	zinc finger and BTB domain containing 20	Intron	Нуро	1.3

\*Methylation changes with fold changes in gene expression by CS+KO vs CS+WT. Hyper, hypermethylation; Hypo, hypomethylated; Inc, increased variance.

Cellular component/Biologic process/Molecular function	Genes	Count	P value
regulation of MAPK cascade	Osm, Tlr6, Irak3, F2r, Fn1, Gdf10, Ncf1, Lmnb1, Map3k7cl, Kdr, Dusp6, Ntrk2	12	1.40729E-05
regulation of interleukin-6 production	Tlr6, F2r, Zbtb20, Cebpb, Irak3	5	2.34084E-05
MAPK cascade	<mark>Osm, Tlr6</mark> , Irak3, F2r, Map3k7cl, Fn1, Ncf1, Kdr, Gdf10, Dusp6, Ntrk2, Lmnb1	12	3.43092E-05
inflammatory response	Cxcl1, Alox5ap, Mmp25, Tlr6, F2r, Tnfrsf1a, Ly86, Fn1, Ncf1, Socs3	10	9.48037E-05
defense response	Tlr6, Mmp25, Cxcl1, Alox5ap, Padi4, Kcnj8, F2r, Zbp1, Socs3, Tnfrsf1a, Ly86, Fn1, Ncf1, Cebpb, rak3, Ifitm2	16	0.000251799
positive regulation of MAPK cascade	<mark>Osm, Tlr6</mark> , F2r, Lmnb1, Map3k7cl, Kdr, Ncf1, Ntrk2	8	0.000312195
response to cytokine	Cxcl1, Osm, Ppargc1a, Ifitm2, Zbp1, Irak3, Cebpb, Krt18, Tnfrsf1a, Gclc, Socs3	11	0.000511441
negative regulation of cytokine production	Tlr6, Srgn, Irak3, Cd84, Fn1	5	0.000563016
cytokine-mediated signaling pathway	Cxcl1, Osm, Irak3, Zbp1, Socs3, Tnfrsf1a, Krt18	7	0.000723893
regulation of cytokine production	Srgn, Tlr6, F2r, Irak3, Cd84, Fn1, Cebpb, Zbtb20	8	0.001398345
regulation of cytokine secretion	Srgn, Tlr6, Fn1, F2r	4	0.001544646
cellular response to cytokine stimulus	Cxcl1, Osm, Socs3, Krt18, Tnfrsf1a, Cebpb, Ppargc1a, Zbp1, Irak3	9	0.002115125
cytokine secretion	Tlr6, Srgn, Fn1, F2r	4	0.002629006
cytokine production	Tlr6, Srgn, Irak3, Cd84, F2r, Cebpb, Fn1,	8	0.002833485

Table S2. GO enrichment analysis (the functional methylated genes marked red)

### Zbtb20

regulation of MAP kinase activity	Tlr6, F2r, Irak3, Map3k7cl, Dusp6	5	0.002862216
immune system process	Psmb9, Tlr6, Cxcl1, Osm, Galnt2, Kcnj8, Zbp1, Tnfrsf1a, Ncf1, Padi4, Cd80, Cd84, Thy1, Blm, Irak3, Ifitm2, Ly86, Cebpb	18	0.008472928
negative regulation of immune system process	Tlr6, Cd84, Irak, Thy1, Cebpb	5	0.015585279
positive regulation of immune system process	Tlr6, Cxcl1, Cd80, Blm, Cd84, Irak3, Zbp1, Thy1	8	0.024008534
immune response	Osm, Tlr6, Cxcl1, Tnfrsf1a, Ly86, Ifitm2, Irak3, Padi4, Thy1, Zbp1,Cd84	11	0.031630554

Pathways	Count	Genes	P value
TNF signaling pathway	4	Cxcl1, Socs3, Tnfrsf1a, Cebpb	0.00164
DNA replication	2	Rnaseh2b, Rfc5	0.00333
IL-17 signaling pathway	2	Cxcl1, Cebpb	0.04311
Toll-like receptor signaling pathway	2	Tlr6, Cd80	0.05491

## Table S3 KEGG enrichment analysis

(the functional methylated genes marked red)